Founded in Canada, MedX is creating a new standard for understanding skin health through precise imaging technologies, with a growing global footprint across 37 territories.

The MedX platform delivers real time, non-invasive measurement of skin chromophores, providing objective clinical data on the biological markers that define skin health including collagen, melanin, and hemoglobin.

By revealing biological signals beneath the surface of the skin, MedX enables clinicians and researchers to move beyond visual assessment toward measurable, data driven insight. Through longitudinal chromophore mapping, biological changes in the skin can be measured and tracked over time.

What began as a mission to eliminate skin cancer through earlier detection has evolved into a robust skin health ecosystem. Today, MedX technologies support clinical detection, research, and large-scale health initiatives through a unified architecture built on chromophore intelligence.

This powerful platform is trusted by more than 85,000 clinically reviewed subsurface images, 14 peer reviewed validations, and deployment worldwide. MedX technologies operate within global regulatory frameworks including FDA, ISO, CE, HIPAA, and MDSAP standards, ensuring the clinical rigor, data integrity, and compliance required by healthcare organizations and research partners around the world.

MedX’s core purpose is to prove skin health through precise imaging technologies.